Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-arm, Ib/II Exploratory Study of Becotatugvedotin(MRG003) in Combination With Gemcitabine for Second-line Advanced Pancreatic Ductal Adenocarcinoma

NCT07685470 is registered in ClinicalTrials.gov with Peking Union Medical College Hospital as lead sponsor.

NCT NCT07685470
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07685470 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-arm, Ib/II Exploratory Study of Becotatugvedotin(MRG003) in Combination With Gemcitabine for Second-line Advanced Pancreatic Ductal Adenocarcinoma
Lead sponsor
Peking Union Medical College Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 8, 2026
Completion date
June 7, 2029
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma (pdac), second line treatment